Key Insights

Highlights

Success Rate

90% trial completion (above average)

Published Results

70 trials with published results (21%)

Research Maturity

201 completed trials (61% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

7.0%

23 terminated out of 329 trials

Success Rate

89.7%

+3.1% vs benchmark

Late-Stage Pipeline

24%

78 trials in Phase 3/4

Results Transparency

35%

70 of 201 completed with results

Key Signals

70 with results90% success23 terminated

Data Visualizations

Phase Distribution

305Total
Not Applicable (183)
Early P 1 (1)
P 1 (12)
P 2 (31)
P 3 (45)
P 4 (33)

Trial Status

Completed201
Recruiting45
Terminated23
Unknown22
Active Not Recruiting17
Not Yet Recruiting14

Trial Success Rate

89.7%

Benchmark: 86.6%

Based on 201 completed trials

Clinical Trials (329)

Showing 20 of 20 trials
NCT06537128Not ApplicableActive Not Recruiting

Internet-delivered Cognitive-Behavioral Therapy for Adolescents With Autism and Anxiety

NCT07856420Phase 3Not Yet RecruitingPrimary

A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment

NCT06909669Not ApplicableRecruiting

Ultra-brief Psychological Treatments for Emotional Symptoms and Disorders

NCT07807865Phase 3RecruitingPrimary

A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as an Additional Treatment in Participants With Generalized Anxiety Disorder (GAD)

NCT06701903Phase 2RecruitingPrimary

Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder

NCT06741228Phase 3Active Not RecruitingPrimary

A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)

NCT06480383Phase 2RecruitingPrimary

Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

NCT07489651Phase 2RecruitingPrimary

RE104 Safety and Efficacy Study in Generalized Anxiety Disorder

NCT07759128Phase 3RecruitingPrimary

A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder

NCT05749055Phase 2CompletedPrimary

ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder

NCT07821840Not ApplicableNot Yet RecruitingPrimary

CannaRiver CBD Calm for Anxiety, Sleep, and Well-Being in Adults With Generalized Anxiety Disorder

NCT07686354Not ApplicableNot Yet Recruiting

LIFU for Chronic Pain and Generalized Anxiety Disorder

NCT07767903Phase 3RecruitingPrimary

A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder

NCT07770919Not ApplicableRecruitingPrimary

Continuous Theta Burst Stimulation for Generalized Anxiety Disorder

NCT06809595Phase 3Active Not RecruitingPrimary

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

NCT06046170Not ApplicableCompleted

Adaptation and Feasibility of the Community-Based Anxiety Program Tailored for Autism (CAPTA)

NCT05967468Not ApplicableActive Not Recruiting

Evaluation of Family-Based Behavioral Treatments for Youth With Anxiety and Obsessive-Compulsive Disorder

NCT06506253Not ApplicableCompletedPrimary

Massage for GAD: Neuroimaging and Clinical Correlates of Response

NCT07786454Phase 3Not Yet RecruitingPrimary

A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety Disorder

NCT07774481Not ApplicableRecruiting

Anxiety Skills Study

Scroll to load more

Research Network

Activity Timeline